Clesrovimab
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
Merck’s Investigational RSV Antibody, Clesrovimab, Meets Primary Safety and Efficacy Endpoints in Phase 2b/3 Trial for Infant Prevention
Merck, RSV, Clesrovimab, Monoclonal Antibody, Infant Prevention, Respiratory Syncytial Virus, Phase 2b/3 Trial